أرسل هذا في رسالة قصيرة: Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally?

 __   __   __   __     _____   __   __    ______  
 \ \\/ //  \ \\/ //   / ___//  \ \\/ //  /_   _// 
  \   //    \ ` //    \___ \\   \ ` //     | ||   
  / . \\     | ||     /    //    | ||     _| ||   
 /_//\_\\    |_||    /____//     |_||    /__//    
 `-`  --`    `-`'   `-----`      `-`'    `--`